K-numberK250502
Device nameSafeSource Direct Blue Powder-Free Nitrile Exam Gloves (AMERI-TUFF Series 4000, AMERI-TOUCH Series 5000)
ApplicantSafesource Direct, LLC
Product codeLZA
Device classClass I
Decision dateMar 19, 2025
DecisionSubstantially Equivalent
Regulation880.6250
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

SafeSource Direct Blue Powder-Free Nitrile Exam Gloves are disposable patient examination gloves worn by examiners to prevent contamination between patient and examiner. The gloves are available in two product lines (AMERI-TUFF Series 4000 and AMERI-TOUCH Series 5000) across multiple sizes (XS to XXL) and have been tested for compatibility with chemotherapy drugs per ASTM D6978-05.

Technological characteristics

Both subject and predicate devices are blue, powder-free, nitrile exam gloves with identical physical properties (tensile strength ≥14 MPa before and after aging, elongation 500% min before aging and 400% after aging, thickness ≥0.05mm). The subject device adds two new sizes (XS and XXL for Series 4000; XS through XXL for Series 5000) and introduces a new product line (Series 5000) alongside the predicate's Series 4000. Dimensions comply with ASTM D6319-19, and all other material, structural, and biocompatibility characteristics remain identical.

Test standards cited

ASTM D6319-19 (dimensions and physical properties), ASTM D5151-06 (watertightness/hole detection), ASTM D6124 (powder content), ASTM D412 (tensile strength and elongation), ASTM D6978-05 Reapproved 2019 (permeation by chemotherapy drugs), ISO 10993-10 (skin irritation and sensitization), ISO 10993-5 (cytotoxicity), ISO 10993-11 (acute systemic toxicity).

Substantial equivalence argument

The subject device maintains identical technological characteristics, materials, manufacturing specifications, and regulatory classification to the predicate device K222898. Non-clinical performance testing demonstrates that all chemotherapy drug permeation times for Series 4000 are identical to the predicate, and Series 5000 achieves the same protective function despite slightly shorter breakthrough times for Carmustine and Thio-Tepa (still providing adequate clinical protection with warnings for drugs with breakthrough times <120 minutes). The addition of new sizes and a new product line does not alter the fundamental design, intended use, or safety profile, as all sizes comply with the same dimensional and performance standards.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →